PEPG Stock Forecast: PepGen Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.78
−3.82% on the day

The median 12-month analyst price target for PepGen Inc. is $15. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$356.3M
Ticker Nerd rank
53/ 100
Median analyst target
$15
Analysts covering
8
Revenue$0.0
Operating income−$18.9M
Net income−$17.8M
Free cash flow−$15.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.3%
1M
+31.7%
YTD
−41.9%
1Y
−25.7%
From 52W high
−47.3%
From 52W low
+180.0%
$1.35
$7.17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores PepGen Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
53/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
79
Accruals
75
Issuance
59
Value
58
Momentum
50
Quality
39
Revisions
28
Volatility
18

Growth (79): Sales and profits are climbing, and climbing faster than before.

Volatility (18): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PEPG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PEPG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26PEPGHigh $20Median $15Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7
Buy
1
Hold
0
Sell
$6
Low
$15
Median
$20
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2026GuggenheimMaintainsBuy$7.00 → $15
11 Nov 2026WedbushMaintainsOutperform$4.00 → $10
9 Sept 2026HC Wainwright & Co.ReiteratesBuy$20
16 June 2026Craig-HallumInitiatesBuy$11
13 May 2026WedbushMaintainsOutperform—
1 Apr 2026WedbushMaintainsOutperform—
31 Mar 2026WedbushMaintainsOutperform—
25 Feb 2026OppenheimerInitiatesOutperform—
18 Feb 2026GuggenheimMaintainsBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
27 Oct 2025HC Wainwright & Co.MaintainsBuy—
30 Sept 2025WedbushMaintainsOutperform—
25 Sept 2025HC Wainwright & Co.MaintainsBuy—
25 Sept 2025StifelMaintainsBuy—
25 Sept 2025WedbushMaintainsOutperform—
24 Sept 2025GuggenheimReiteratesBuy—
9 Sept 2025GuggenheimInitiatesBuy—
29 May 2025HC Wainwright & Co.MaintainsBuy—
9 May 2025HC Wainwright & Co.MaintainsBuy—
24 Feb 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PEPG.

Market Radar

This page is one stock. Monday covers all of them.

PEPG appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PEPG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, PepGen Inc. returned −25.7% against +6.9% for the S&P 500, dividends included.

PEPG vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26PEPGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PEPG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.5×

Cheaper than 35% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−55.1%

Higher than 20% of US stocks

Return on assets
−30.7%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PepGen Inc. has a market value of $356.3M and an enterprise value of $172.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$71.9M.

  • Diluted earnings per share, trailing twelve months: −$1.31.

  • Free cash flow in the twelve months to 30 June 2026: −$69.5M.

  • Shares outstanding: 69.3M.

  • PepGen Inc. employs 53 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

PEPG and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PEPGPepGen Inc.$356.3M53
OCGNOcugen, Inc.$259.9M43
ALTAltimmune, Inc.$258.5M11
KYTXKyverna Therapeutics, Inc.$257.5M34
PRLDPrelude Therapeutics, Inc.$257.3M92
AGENAgenus, Inc.$267.2M82
EIKNEikon Therapeutics, Inc.$256.4M5

Take a look at PEPG’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own PepGen Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PEPG

What is the PEPG stock price forecast for 2026-2027?

The median 12-month analyst price target for PepGen Inc. is $15, with estimates ranging from $6 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PEPG stock a buy right now?

Of the 8 analysts covering PepGen Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PepGen Inc. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PEPG?

As at 21 Nov 2026, PepGen Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).

Will PEPG stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts is $15, and Ticker Nerd's factor model ranks PepGen Inc. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PEPG stock forecast for 2030?

No analyst covering PepGen Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PEPG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $20 over the next 12 months.

How has PEPG stock performed over the past year?

PepGen Inc. returned -25.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PepGen Inc. do?

PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company’s work centers on its proprietary Enhanced Delivery Oligonucleotide platform, which is designed to improve the delivery, uptake, and activity of conjugated oligonucleotide medicines in targeted tissues.

Company

About PepGen Inc.

PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company’s work centers on its proprietary Enhanced Delivery Oligonucleotide platform, which is designed to improve the delivery, uptake, and activity of conjugated oligonucleotide medicines in targeted tissues. PepGen’s current pipeline includes investigational programs for conditions such as Duchenne muscular dystrophy and myotonic dystrophy type 1, with several candidates in clinical development and additional programs in earlier stages. By concentrating on genetic disorders with high unmet medical need, PepGen aims to advance precision therapeutics that address the underlying cause of disease rather than only managing symptoms. The company is headquartered in Boston, Massachusetts.

CEO Dr. James G. McArthur Ph.D. · 53 employees · United States · https://www.pepgen.com